A Comparison of CD4 T Cell Induction and Antibody Responses Between a Pure Hemagglutinin Influenza Vaccine (rHA, Protein Sciences Corp) and Licensed Subvirion Influenza Vaccine Made in Eggs (Sanofi) or Cell Culture (Novartis) in Healthy Adults.

Trial Profile

A Comparison of CD4 T Cell Induction and Antibody Responses Between a Pure Hemagglutinin Influenza Vaccine (rHA, Protein Sciences Corp) and Licensed Subvirion Influenza Vaccine Made in Eggs (Sanofi) or Cell Culture (Novartis) in Healthy Adults.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 May 2018

At a glance

  • Drugs Influenza vaccine (Optaflu) (Primary) ; Influenza virus RIV3 vaccine-(FluBlok) (Primary) ; Influenza virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 30 Apr 2018 Planned End Date changed from 30 Jun 2018 to 30 Jun 2020.
    • 30 Apr 2018 Planned primary completion date changed from 30 Jun 2018 to 30 Jun 2019.
    • 08 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top